vs

Side-by-side financial comparison of Chatham Lodging Trust (CLDT) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.

Chatham Lodging Trust is the larger business by last-quarter revenue ($67.7M vs $62.1M, roughly 1.1× Cytek Biosciences, Inc.). Chatham Lodging Trust runs the higher net margin — 6.8% vs -70.9%, a 77.7% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -9.8%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -0.5%).

Chatham Lodging Trust is a publicly traded real estate investment trust that invests in, owns, and operates upscale extended-stay and select-service premium hotel properties primarily across high-demand urban and suburban markets in the United States. Its portfolio targets assets with strong occupancy rates and steady cash flow from business and leisure traveler segments.

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

CLDT vs CTKB — Head-to-Head

Bigger by revenue
CLDT
CLDT
1.1× larger
CLDT
$67.7M
$62.1M
CTKB
Growing faster (revenue YoY)
CTKB
CTKB
+17.9% gap
CTKB
8.1%
-9.8%
CLDT
Higher net margin
CLDT
CLDT
77.7% more per $
CLDT
6.8%
-70.9%
CTKB
Faster 2-yr revenue CAGR
CTKB
CTKB
Annualised
CTKB
17.7%
-0.5%
CLDT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLDT
CLDT
CTKB
CTKB
Revenue
$67.7M
$62.1M
Net Profit
$4.6M
$-44.1M
Gross Margin
52.9%
Operating Margin
15.9%
-9.0%
Net Margin
6.8%
-70.9%
Revenue YoY
-9.8%
8.1%
Net Profit YoY
369.9%
-557.1%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLDT
CLDT
CTKB
CTKB
Q4 25
$67.7M
$62.1M
Q3 25
$78.4M
$52.3M
Q2 25
$80.3M
$45.6M
Q1 25
$68.6M
$41.5M
Q4 24
$75.1M
$57.5M
Q3 24
$87.2M
$51.5M
Q2 24
$86.5M
$46.6M
Q1 24
$68.4M
$44.9M
Net Profit
CLDT
CLDT
CTKB
CTKB
Q4 25
$4.6M
$-44.1M
Q3 25
$3.5M
$-5.5M
Q2 25
$5.4M
$-5.6M
Q1 25
$1.5M
$-11.4M
Q4 24
$-1.7M
$9.6M
Q3 24
$4.3M
$941.0K
Q2 24
$6.8M
$-10.4M
Q1 24
$-5.2M
$-6.2M
Gross Margin
CLDT
CLDT
CTKB
CTKB
Q4 25
52.9%
Q3 25
52.7%
Q2 25
52.3%
Q1 25
48.6%
Q4 24
40.7%
58.5%
Q3 24
44.7%
56.3%
Q2 24
46.1%
54.6%
Q1 24
38.9%
51.3%
Operating Margin
CLDT
CLDT
CTKB
CTKB
Q4 25
15.9%
-9.0%
Q3 25
12.7%
-17.6%
Q2 25
14.8%
-23.3%
Q1 25
12.1%
-36.1%
Q4 24
7.5%
5.2%
Q3 24
14.3%
-8.2%
Q2 24
16.3%
-18.3%
Q1 24
1.4%
-23.9%
Net Margin
CLDT
CLDT
CTKB
CTKB
Q4 25
6.8%
-70.9%
Q3 25
4.5%
-10.5%
Q2 25
6.7%
-12.2%
Q1 25
2.2%
-27.5%
Q4 24
-2.3%
16.8%
Q3 24
4.9%
1.8%
Q2 24
7.9%
-22.4%
Q1 24
-7.6%
-13.8%
EPS (diluted)
CLDT
CLDT
CTKB
CTKB
Q4 25
$0.05
Q3 25
$0.03
Q2 25
$0.07
Q1 25
$-0.01
Q4 24
$-0.08
Q3 24
$0.05
Q2 24
$0.10
Q1 24
$-0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLDT
CLDT
CTKB
CTKB
Cash + ST InvestmentsLiquidity on hand
$24.4M
$90.9M
Total DebtLower is stronger
$338.9M
Stockholders' EquityBook value
$740.8M
$341.7M
Total Assets
$1.2B
$461.5M
Debt / EquityLower = less leverage
0.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLDT
CLDT
CTKB
CTKB
Q4 25
$24.4M
$90.9M
Q3 25
$13.2M
$93.3M
Q2 25
$17.2M
$75.5M
Q1 25
$18.6M
$95.3M
Q4 24
$20.2M
$98.7M
Q3 24
$19.3M
$162.3M
Q2 24
$10.6M
$177.9M
Q1 24
$72.3M
$168.8M
Total Debt
CLDT
CLDT
CTKB
CTKB
Q4 25
$338.9M
Q3 25
$338.8M
Q2 25
$351.2M
Q1 25
$381.1M
Q4 24
$406.9M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CLDT
CLDT
CTKB
CTKB
Q4 25
$740.8M
$341.7M
Q3 25
$749.4M
$378.6M
Q2 25
$754.1M
$377.6M
Q1 25
$754.7M
$379.6M
Q4 24
$758.2M
$395.7M
Q3 24
$765.3M
$385.5M
Q2 24
$766.5M
$389.1M
Q1 24
$765.0M
$392.6M
Total Assets
CLDT
CLDT
CTKB
CTKB
Q4 25
$1.2B
$461.5M
Q3 25
$1.2B
$494.9M
Q2 25
$1.2B
$493.3M
Q1 25
$1.2B
$482.6M
Q4 24
$1.3B
$499.5M
Q3 24
$1.3B
$491.2M
Q2 24
$1.3B
$483.7M
Q1 24
$1.3B
$492.1M
Debt / Equity
CLDT
CLDT
CTKB
CTKB
Q4 25
0.46×
Q3 25
0.45×
Q2 25
0.47×
Q1 25
0.50×
Q4 24
0.54×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLDT
CLDT
CTKB
CTKB
Operating Cash FlowLast quarter
$64.1M
$-771.0K
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-2.9%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
13.90×
TTM Free Cash FlowTrailing 4 quarters
$-8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLDT
CLDT
CTKB
CTKB
Q4 25
$64.1M
$-771.0K
Q3 25
$25.6M
$-3.9M
Q2 25
$22.1M
$108.0K
Q1 25
$4.2M
$-125.0K
Q4 24
$73.8M
$2.0M
Q3 24
$28.8M
$13.2M
Q2 24
$25.2M
$6.2M
Q1 24
$6.9M
$4.0M
Free Cash Flow
CLDT
CLDT
CTKB
CTKB
Q4 25
$-1.8M
Q3 25
$-4.6M
Q2 25
$-1.5M
Q1 25
$-974.0K
Q4 24
$1.1M
Q3 24
$12.2M
Q2 24
$5.2M
Q1 24
$3.4M
FCF Margin
CLDT
CLDT
CTKB
CTKB
Q4 25
-2.9%
Q3 25
-8.7%
Q2 25
-3.2%
Q1 25
-2.3%
Q4 24
1.9%
Q3 24
23.7%
Q2 24
11.0%
Q1 24
7.6%
Capex Intensity
CLDT
CLDT
CTKB
CTKB
Q4 25
1.6%
Q3 25
1.3%
Q2 25
3.5%
Q1 25
2.0%
Q4 24
1.6%
Q3 24
2.0%
Q2 24
2.3%
Q1 24
1.3%
Cash Conversion
CLDT
CLDT
CTKB
CTKB
Q4 25
13.90×
Q3 25
7.24×
Q2 25
4.10×
Q1 25
2.73×
Q4 24
0.21×
Q3 24
6.78×
14.05×
Q2 24
3.68×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLDT
CLDT

Occupancy$61.5M91%
Hotel Other$4.2M6%
Food And Beverage$1.8M3%
Hotel$1.1M2%

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

Related Comparisons